Inactive Instrument

TiGenix NV Share Price

Equities

TIG

BE0003864817

Biotechnology & Medical Research

Chart TiGenix NV

Duration

Period

Style

Latest news about TiGenix NV

Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	29/18/29	RE
Takeda Pharmaceutical : Japan's Takeda hikes outlook on cancer drug sales, third quarter profit jumps	01/18/01	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/18/22	RE
Takeda Pharmaceutical : Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid	08/18/08	RE
Takeda Pharmaceutical : $11 billion biotech binge fuels forecasts of 2018 M&A surge	08/18/08	RE
GALAPAGOS : Maturing Belgian biotechs outshine European peers	04/12/04	RE

Press releases TiGenix NV

TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN - NL - FR - ES)	31/18/31	PU
TiGenix : Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period	31/18/31	GL
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007	24/18/24	GL
TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations (EN – NL – FR – ES)	06/18/06	PU
TiGenix : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid	06/18/06	GL

More press releases

News in other languages on TiGenix NV

TiGenix : Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait	31/18/31
Le Graph du Jour : 29% des biotechs en territoire positif depuis leur IPO sur Euronext	23/18/23
TiGenix : Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix	06/18/06
TiGenix : annonce un changement dans son conseil d'administration et son équipe de direction	13/18/13
TiGenix : Takeda et TiGenix annoncent les résultats de la première période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix et le début de la deuxième période d'accep...	06/18/06

Managers and Directors - TiGenix NV

Managers	Title	Age	Since
Wilfried Dalemans CTO	Chief Tech/Sci/R&D Officer	66	-
Koen Huygens PRN	Corporate Officer/Principal	-	01/01/01
Julian Panes PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Sebastian Wehle BRD	Director/Board Member	-	15/18/15
Jean Stephenne CHM	Chairman	75	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.05%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.28%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer